Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension phase ...

Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...

Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...

AlzeCure Pharma AB has announced it has received the first payment of a EUR 2.5 million grant from the European Innovation Council (EIC). The funding will support a phase 2a clinical study of the ...

Young people are our future workforce, so it’s important that companies have a youth-positive culture. To be competitive, ...

The phase 1 trial, VNA-318-01, was a randomized, double-blind study involving 92 healthy male subjects. Interim results ...

Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as President and Chief Executive Officer. She ...

SERB Pharmaceuticals has appointed Dr Vignesh Rajah as its new Chief Medical Officer, bringing over 20 years of global ...

Two became one at the Grand Connaught Rooms in London as a joyous jamboree of marketing and communications excellence, all ...

“2025 has been a year where both geopolitics and the promise of AI have influenced the dynamics in this industry,” says Frits ...

The old model of ‘pushing’ a message is dead. The new game is about earning trust, proving your humanity and co-creating.

We’re in the midst of a rapidly evolving UK environment for the life sciences industry, with a dynamic shift in our ...